Continuous Erythropoietin Receptor Activator (C.E.R.A.) is a new agent that in development for the treatment of anemia with extended administration intervals patients who have chronic kidney disease (CKD), both those on and not dialysis. This was an open-label, randomized, multicenter, two-period, crossover study erythropoiesis-stimulating agentnaïve had CKD were receiving peritoneal After 1-wk run-in period, 16 randomly assigned to receive single intravenous C.E.R.A. 0.4 microg/kg (n = 8)...

The mechanisms of clearance circulating plasma DNA are not fully understood, and so we aimed to examine it in patients with impaired renal function compared healthy individuals. We also assessed the effect peritoneal dialysis hemodialysis on cell‐free (cfDNA) our treated patients. Overall, 20 volunteers, chronic kidney disease (CKD), 18 undergoing (PD), 17 (HD; high‐flux polysulfone membrane) were examined. Cell‐free levels determined using real‐time GADPH gene sequence amplification. cfDNA...

Abstract Asymmetric dimethylarginine (ADMA) is a mediator of endothelial dysfunction. Production and elimination ADMA may be affected by the type renal replacement therapy used oxidative stress. Plasma ADMA, advanced glycation end products (AGE), homocysteine were assessed in 59 subjects: 20 hemodialysis (HD) patients, 19 patients undergoing peritoneal dialysis (PD), controls. Results compared between groups. The effect 8 weeks HD high‐volume predilution hemodiafiltration (HDF) was...

To examine whether the levels of procalcitonin (PCT), a new marker infection and/or inflammation, differ between peritoneal dialysis (PD) patients and healthy volunteers, PCT is detectable in uninfected drained dialysate.Observational cross-sectional study.PD unit, department medicine, university hospital.A total 28 PD patients, free systemic infection, age- sex-matched volunteers.PCT was determined by immunoluminometry; detection range 0.01 - 500 ng/mL, reference < 0.5 ng/mL.Plasma were...

Objective In this study, we compared the activity of interleukin-6 (IL-6), a marker ongoing peritoneal inflammation and biocompatibility, its other signaling components, soluble IL-6 receptor (sIL-6R) Gp130 (sGp130), in effluent from patients treated with icodextrin-based (E) dialysis (PD) solution glucose-based bicarbonate/lactate–buffered (P) solution. Methods Using baseline ultrafiltration capacity, 33 stable incident PD were allocated either to P only ( n = 20) or plus E for overnight...

Purpose. Cell-free plasma DNA (cfDNA) levels originating predominantly from apoptotic leukocytes were found to rise during hemodialysis (HD) session, and as such are considered a marker of HD membrane biocompatibility. The purpose our study was determine the changes cfDNA two consecutive high-flux polysulphone sessions after long (HD-L) short (HD-S) interdialytic interval. Methods. A total 17 patients examined. Prior at 30 240 min, (using real-time PCR) leukocyte count determined. Results....

Abstract: Renal anemia significantly affects the morbidity and mortality of dialysis patients. The aim present study was to establish whether severity success its treatment differs when using high‐flux (HF) or low‐flux (LF) hemodialysis. Twenty‐five patients on long‐term hemodialysis with a mean hematocrit (Hct) 33%, S alb 36 g/L, Kt/V urea 1.5 were divided into Groups X (n = 13) Y 12) in prospective randomized crossover study. Group initially treated LF be followed by HF for 8 weeks each...

&lt;b&gt;Aim:&lt;/b&gt; To establish whether the values of two key enzymes fibrinolysis, tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1), differ between patients treated with continuous ambulatory peritoneal dialysis (CAPD) healthy volunteers plasma dialysate tPA PAI-1 vary during one exchange solution. &lt;b&gt;Methods:&lt;/b&gt; A total 11 chronic renal failure, CAPD equilibration test (in addition blood sampling at time 0), a control group were examined. identify factors...

&lt;i&gt;Background/Aims:&lt;/i&gt; Patients with chronic renal failure (CRF) secondary to diabetes mellitus show a high incidence of atherosclerosis its thrombotic complications. Both CRF and type 2 (DM2) results in fibrinolysis defects causally related atherogenesis thrombogenesis. It is not well known whether or and, if so, how altered patients both DM2. Our study was designed (1) identify the defect present DM2-mediated treated by long-term hemodialysis (DM2HD), (2) establish metabolic...

The healthcare system of the Czech Republic at time country was made part Eastern Bloc characterized by scarcity funds as a result its poorly functioning economy combined with difficult access to up-to-date medical information because restricted communication Western democracies. These were main causes for medicine lagging behind that industrialized nations. political changes occurring in 1989 soon followed economic and societal led to, among other things, badly needed reform, gradually...

&lt;i&gt;Background/Aim:&lt;/i&gt; The tissue factor (TF) plays a key role in triggering the coagulation system vivo. Our study was designed to determine whether or not plasma levels of TF and its pathway inhibitor (TF inhibitor; TFPI) patients with chronic renal failure (CRF) treated by peritoneal dialysis (PD) (1) are pathologically altered; (2) differ between diabetics nondiabetics, (3) depend on metabolic disorders associated CRF and/or diabetes. &lt;i&gt;Methods:&lt;/i&gt; Using ELISA,...

Abstract Intraperitoneal glucose degradation products ( GDP ) load influences systemic advanced glycation end AGEs but the effects on soluble receptor for (s‐ RAGE and its proinflammatory ligands: extracellular newly identified end‐products binding protein( EN‐RAGE high mobility group box‐1 protein HMGB ‐1) are unknown. We aimed to compare plasma peritoneal s‐ , ‐1 between three dialysis PD) prescription regimens with different intraperitoneal loads. High (glucose‐lactate PD fluid, D ; N =...

Background. Evaluation of acid-base disorders using the Stewart-Fencl principle is based on assessment independent factors: strong ion difference (SID) and total concentration non-volatile weak acids (Atot). This approach allows for a more detailed evaluation cause imbalance than conventional bicarbonate-centered Henderson-Hasselbalch principle, which necessary yet insufficient condition to describe state system. The aim our study was assess in peritoneal dialysis (PD) patients both these...

Abstract: Two studies designed to investigate the effect of recombinant human erythropoietin (rHuEPO) treatment anemia in chronic dialysis patients on hemocompatibility were conducted. Study 1, whose main aim was establish whether with rHuEPO enhances coagulation activation during dialysis, included 15 before therapy at a mean hematocrit (HCT) 22.3% and then HCT 29.3%. The plasma concentrations thrombin‐antithrombin III complex not higher than it when performing hemodialysis Cuprophan...

Anemia in chronic renal failure causes a number of serious problems to the patient. As result, it is imperative make use all rational options alleviate it. The present study addresses question, answer which not yet known, whether or degree anemia depends on efficacy continuous ambulatory peritoneal dialysis (CAPD) and, if so, what importance clearance and residual function is. A significant correlation between hematocrit (Hct) total weekly Kt/V index (tKt/V) (r = 0.61, p &lt; 0.01),...

Abstract Icodextrin peritoneal dialysis (PD) solution has been shown to increase interleukin‐6 (IL‐6) levels in PD effluent as well leukocyte and mesothelial cell count. Mesothelial cells release cancer antigen 125 (CA125), which is used a marker of mass. This 1‐year prospective study was designed compare population, its inflammatory phenotype biocompatibility biomarkers IL‐6 CA125 between icodextrin (E) glucose bicarbonate/lactate (P) based solutions. Using baseline ultrafiltration...